Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy

Obstetrics and Gynecology

Volumn 127, Issue 3, 2016, Pages 553-561

  Hanley, Gillian E ^a   Smolina, Kate ^a   Mintzes, Barbara ^a   Oberlander, Tim F ^a   Morgan, Steven G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIRTH WEIGHT; BODY MASS; CESAREAN SECTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EPISIOTOMY; FEMALE; HEALTH STATUS; HUMAN; ICD-10; ICD-9; LABOR; LABOR INDUCTION; LABOR STAGE 3; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MONOTHERAPY; MOOD DISORDER; PERINATAL DRUG EXPOSURE; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VAGINAL DELIVERY; CHEMICALLY INDUCED; PREGNANCY COMPLICATIONS;

ADULT; FEMALE; HUMANS; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84960443661     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001200     Document Type: Article

References (51)

1. Baskett TF, O'Connell CM. Severe obstetric maternal morbidity: A 15-year population-based study. J Obstet Gynaecol 2005; 25:7-9.
2. Gilbert TT, Smulian JC, Martin AA, Ananth CV, Scorza W, Scardella AT, et al. Obstetric admissions to the intensive care unit: outcomes and severity of illness. Obstet Gynecol 2003; 102:897-903.
3. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010;110:1368-73.
4. Blomberg M. Maternal obesity and risk of postpartum hemorrhage. Obstet Gynecol 2011;118:561-8.
5. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol 2010;202:353.e1-6.
6. Ford JB, Roberts CL, Simpson JM, Vaughan J, Cameron CA. Increased postpartum hemorrhage rates in Australia. Int J Gynaecol Obstet 2007;98:237-43.
7. Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF; Maternal Health Study Group of the Canadian Perinatal Surveillance System. Investigation of an increase in postpartum haemorrhage in Canada. BJOG 2007;114:751-9.
8. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, et al. Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 2009;9:55.
9. Lutomski JE, Byrne BM, Devane D, Greene RA. Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. BJOG 2012;119:306-14.
10. Rossen J, Okland I, Nilsen OB, Eggebø TM. Is there an increase of postpartum hemorrhage, and is severe hemorrhage associated with more frequent use of obstetric interventions? Acta Obstet Gynecol Scand 2010;89:1248-55.
11. NHS Scotland. Scottish confidential audit severe maternal morbidity: reducing avoidable harm. Edinburgh (Scotland): Healthcare Improvement Scotland; 2014.
12. Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM, Joseph KS. Epidemiological investigation of a temporal increase in atonic postpartum haemorrhage: A populationbased retrospective cohort study. BJOG 2013;120:853-62.
13. Mehrabadi A, Hutcheon JA, Lee L, Liston RM, Joseph KS. Trends in postpartum hemorrhage from 2000 to 2009: A population-based study. BMC Pregnancy Childbirth 2012;12:108.
14. Mehrabadi A, Liu S, Bartholomew S, Hutcheon JA, Kramer MS, Liston RM, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. J Obstet Gynaecol Can 2014;36:21-33.
15. Joseph KS, Sheehy O, Mehrabadi A, Urquia ML, Hutcheon JA, Kramer M, et al. Can drug effects explain the recent temporal increase in atonic postpartum haemorrhage? Paediatr Perinat Epidemiol 2015;29:220-31.
16. Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S. Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. PLoS One 2015;10:e0128312.
17. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth 2014;14:242.
18. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: A retrospective, populationbased study in British Columbia, Canada (2001-2006). Clin Ther 2012;34:239-49.e2.
19. Castro VM, Gallagher PJ, Clements CC, Murphy SN, Gainer VS, Fava M, et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012;2:e000544.
20. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343: d4551.
21. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004;164:2367-70.
22. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-8.
23. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319:1106-9.
24. Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb) 2009:3677-92.
25. Cordeaux Y, Pasupathy D, Bacon J, Charnock-Jones DS, Smith GC. Characterization of serotonin receptors in pregnant human myometrium. J Pharmacol Exp Ther 2009;328:682-91.
26. Palmsten K, Hernández-Diaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013;347:f4877.
27. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
28. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008;28:230-4.
29. Grzeskowiak LE, McBain R, Dekker GA, Clifton VL. Antidepressant use in late gestation and risk of postpartum haemorrhage: A retrospective cohort study. BJOG 2015 [Epub ahead of print].
30. Lupattelli A, Spigset O, Koren G, Nordeng H. Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: A study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2014;34:143-8.
31. BC Ministry of Health. Medical Services Plan (MSP) Payment information file. Population data BC. MOH; 2014. Available at: http://www.popdata.bc.ca/data. Retrieved November 30, 2015.
32. Canadian Institute for Health Information. Discharge abstract database (hospital separations). Vancouver (Canada): Population data BC. Data extract. MOH; 2014. Available at: http://www.popdata.bc.ca/data.
33. Perinatal Services BC. Perinatal Services BC births & stillbirths. Vancouver (Canada): Perinatal Services BC; 2012. Available at: http://www.perinatalservicesbc.ca/DataAndSurveillance/Data Registry/default.htm. Retrieved November 30, 2015.
34. BC Ministry of Health. Consolidation file (MSP registration and premium billing). Vancouver (Canada): Population Data BC, MOH; 2014. Available at: http://www.popdata.bc.ca/data. Retrieved November 30, 2015.
35. Frosst G, Hutcheon J, Joseph KS, Kinniburgh B, Johnson C, Lee L. Validating the British Columbia Perinatal Data Registry: A chart re-abstraction study. BMC Pregnancy Childbirth 2015;15:123.
36. Hu W. Diagnostic codes in MSP Claim data. Victoria (Canada): Program Monitoring and Information Management Branch, Resource Management Division, Medical Services Plan; 1996.
37. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information discharge abstract database: A validation study. Toronto (Ontario, Canada): Institute for Clinical Evaluative Sciences; 2006.
38. O'Donnell J, Shelton R. Drug therapy of depression and anxiety disorders. In: Brunton L, Chabner B, Knolllman B, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York (NY): McGraw-Hill; 2011.
39. De Vera MA, Bérard A. Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol 2012;74:362-9.
40. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline-and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999; 48:345-54.
41. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-9.
42. Melichar JK, Haida A, Rhodes C, Reynolds AH, Nutt DJ, Malizia AL. Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. J Psychopharmacol 2001;15:9-12.
43. Siepmann T, Ziemssen T, Mueck-Weymann M, Kirch W, Siepmann M. The effects of venlafaxine on autonomic functions in healthy volunteers. J Clin Psychopharmacol 2007;27: 687-91.
44. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):15-20.
45. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-9.
46. Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006;14:796-802.
47. Kok R, Nolen W, Heeren T. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2007;15:725.
48. Charniot JC, Vignat N, Monsuez JJ, Kidouche R, Avramova B, Artigou JY, et al. Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine. Am J Emerg Med 2010;28:256.e1-5.
49. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother 2008;42:882-7.
50. Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003;64:875-82.
51. Sheiner E, Sarid L, Levy A, Seidman DS, Hallak M. Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: A population-based study. J Matern Fetal Neonatal Med 2005;18:149-54.